

1 **Defective monocyte enzymatic function and an inhibitory immune phenotype in HIV-**
2 **exposed uninfected African infants in the era of anti-retroviral therapy**

3 Louise Afran^{1,2,3}, Kondwani C. Jambo^{1,3}, Wilfred Nedi¹, David JC Miles^{1,4}, Anmol Kiran^{1,7}, Dominic
4 H Banda¹, Ralph Kamg'ona¹, Dumizulu Tembo¹, Annette Burger⁴, Eleni Nastouli⁶, Brigit Ferne⁶,
5 Henry C Mwandumba^{1,3}, Paul Moss⁴, David Goldblatt⁶, Sarah Rowland-Jones⁵, Adam Finn¹, Robert S
6 Heyderman^{1,6}

7
8 ¹ Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of
9 Medicine, ²Bristol Children's Vaccine Centre, Schools of Cellular & Molecular Medicine and of
10 Population Health Sciences, University of Bristol, Bristol, United Kingdom, ³Department of Clinical
11 Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom, ⁴ University of
12 Birmingham, Birmingham, United Kingdom, ⁵University of Oxford, Nuffield Department of
13 Medicine, Oxford, United Kingdom, and ⁶University College London, Division of Infection and
14 Immunity, United Kingdom, and ⁷University of Edinburgh, United Kingdom..

15
16 Correspondence to: *Louise Afran, Malawi-Liverpool-Wellcome Trust Clinical Research Programme,
17 P.O Box 30096, Chichiri, Blantyre 3, Malawi. Email: Lafran@mlw.mw
18 Tel: +0992118817, +447762367111
19 or Robert S Heyderman, Division of Infection and Immunity University College London, Rayne
20 Building, 5 University Street, London, WC1E 6JF. Email: r.heyderman@ucl.ac.uk
21 Tel: +44 2031087665

22
23 **Keywords.** HIV-exposure, immune dysregulation, monocyte function, neonatal vaccine
24 immunity, HIV-1, ART, Human herpes virus,

25
26 **Summary.** HIV-Exposed Uninfected (HEU) infants are a rapidly expanding population in

27 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
sub-Saharan Africa and are highly susceptible to disease caused by encapsulated bacteria in

28 the first year of life. The mechanism of this increased risk is still poorly understood. We
29 therefore investigated if HIV exposure dysregulates HEU infant immunity and if this is
30 amplified by human herpes virus infection (HHV). Here, we compared monocyte enzymatic
31 function, innate and adaptive immune cell phenotype, and vaccine-induced antibody
32 responses between HEU and HUU infants. We demonstrate altered monocyte phagosomal
33 function and B cell subset homeostasis, and lower vaccine-induced anti-*Haemophilus*
34 *influenzae type b (Hib)* and anti-Tetanus Toxoid (TT) IgG titers in HEU compared to HUU
35 infants. There was no difference in the prevalence of HHV infection between HEU and HUU
36 infants. Our findings suggest that even in the era of antiretroviral therapy (ART)-mediated
37 viral suppression, HIV exposure dysregulates monocyte and B cell function during a
38 vulnerable period of immune maturation in infancy. This may contribute to the high rates of
39 invasive bacterial disease and pneumonia in HEU infants.

40 **Introduction**

41 HIV-exposed uninfected (HEU) infants are more susceptible to infection-related morbidity
42 and mortality^{1,2}. HEU infants are particularly vulnerable to invasive bacterial disease³⁻⁷
43 particularly, pneumonia⁸⁻¹³ and diarrhea^{14,15}, they have more frequent hospitalisations, more
44 severe infections and increased risk of treatment failure. However, the mechanism of this
45 increased vulnerability remains unknown. The global population of children who are HEU is
46 substantial, estimated at 1.2 million births annually, mainly within developing countries¹⁶. A
47 coordinated strategy is therefore necessary to ensure their optimal health and wellbeing¹⁷.

48

49 The vulnerability of HEU infants is a likely complex intersection of HIV-exposure immune
50 profile ‘remodelling’, an ‘inflammatory’ maternal cytokine milieu¹⁸, time of antiretroviral
51 therapy (ART) initiation¹⁹, ART use²⁰ and prophylactics²¹, increased exposure to maternal
52 viral and bacterial pathogens, and host microbial and environmental factors. Together these
53 result in a more permissive state for the development of infections¹. Many observational
54 studies have reported immunological abnormalities in HEU infants²² including highly
55 differentiated T-cells²³⁻²⁹ and B-cell subsets³⁰, altered responses to vaccines³¹⁻³³, functional
56 impairment of natural killer cells³⁴ and monocytes³⁵⁻³⁷. Furthermore, few studies have
57 considered early transmission of immunomodulatory human herpes virus’ (HHVs),
58 cytomegalovirus (CMV)³⁸ and Epstein Barr virus (EBV)³⁹ recrudescence during pregnancy
59 on HEU immunity. HHVs are important as they are implicated in delayed growth^{40,41}, poor
60 neurodevelopment, altered mitochondria DNA⁴² and inflammation in HEU infants^{43,44}.

61

62 Due to the successful HIV test and treat strategy globally, the prevalence of individuals
63 receiving ART has risen considerably¹⁶. Consequently, the number of HEU infants born to
64 mothers receiving ART has increased markedly^{45,46}, but despite expanded maternal use of

65 ART⁴⁷ or implementation of prevention-of-mother-to-child-transmission (PMTCT)
66 programmes⁴⁸, the risk of infection-related morbidity and mortality among HEU infants
67 remains high², particularly the risk of encapsulated bacterial infection^{7,9,49-51}. The immune
68 profile amongst HEU infants in this context is not well documented. We have therefore
69 addressed the question of whether HIV exposure and HHVs dysregulate infant immunity
70 and/or response to primary vaccination. By comprehensive cellular and serological
71 assessment, we show impaired monocyte phagosomal function, altered B cell homeostasis
72 and selective impairment of vaccine-induced anti-Hib antibody response in HEU babies less
73 than 6 months of age. These findings suggest acquired defects in innate and adaptive
74 immunity, heightened regulation of HEU immune responses, which may increase
75 susceptibility to invasive bacterial disease and pneumonia.

76

77 **Results**

78 **Participant characteristics.** We recruited two cohorts to evaluate the impact of HIV
79 exposure and herpes virus infection on immunity at birth and in early infancy. A birth cohort
80 comprised 34 HIV-infected and 44 HIV-uninfected pregnant women. A longitudinal infant
81 cohort comprised 43 HIV-infected and 61 HIV-uninfected mother-infant pairs, who were
82 followed at 3 timepoints, 5-9, 14-15 and 18-23 weeks of age, corresponding to the Malawian
83 routine infant vaccine schedule of: BCG at birth, then pentavalent vaccine at 6, 10 and 14
84 weeks.

85

86 In the birth cohort, two babies were excluded from the analysis due to death and HIV-
87 positivity detected by digital droplet PCR. HIV-infected pregnant women received ART
88 (Option B+) for an average of 18.7 (range 1-143) months, with a mean nadir CD4+ T-cell

89 count of 294 (range 8-892) and were more likely to have had an elective caesarean birth,
90 compared to HIV-uninfected pregnant women (Table 1).

91

92 In the longitudinal infant cohort, HIV-infected mothers had received option B+ for an
93 average of 9.28 (range 1-72) months at the time of enrollment and had a mean nadir CD4+ T-
94 cell count of 409 (range 159-823). There was no difference between maternal age or
95 breastfeeding status but mode of delivery was more often caesarean section in HIV-infected
96 mothers compared to HIV-negative mothers (Table 1).

97

98 **Impaired CD14⁺ monocyte function in HEU new-borns.** Monocytes are an important first
99 line of defence against invasive bacteria, particularly in early life, before the maturation of
100 adaptive immunity^{52,53} and are crucial in controlling bacterial pneumonia⁵⁴⁻⁵⁶. We used a
101 flow cytometry-based whole blood reporter bead assay⁵⁷ to assess monocyte function in cord
102 blood (Figure 1a-b; Supplementary Figure 1). First, we assessed the ability of monocytes to
103 internalise Alexa Fluor 405-labeled IgG-coated reporter beads at 1 hour post co-incubation,
104 as a proxy of uptake capacity. We showed that the proportion of monocytes that internalised
105 reporter beads was similar between HEU infants and HUU controls (Figure 1c). Second, we
106 assessed the phagosomal superoxide burst activity, an important component of intracellular
107 killing by phagocytes⁵⁸, and found that phagosomal superoxide burst activity was lower in
108 monocytes from HEU infants compared to HUU controls (Figure 1d). Third, we assessed the
109 phagosomal bulk proteolytic activity, an important intracellular protein degradation
110 mechanism that impacts antigen-presentation⁵⁹, and showed that the phagosomal bulk
111 proteolytic activity was lower in monocytes from HEU infants compared to HUU controls
112 (Figure 1e). Collectively, these data indicate altered monocyte phagosomal functional
113 capacity at birth in HEU new-borns.

114

115 **Inhibitory B cell phenotype and reduced T cell mitogen response in HEU new-borns.**

116 Having demonstrated altered monocyte phagosomal function which is part of innate
117 immunity in HEU new-borns, we next sought to investigate whether B and T cell subsets are
118 dysregulated. In the B cell compartment, we observed similar distributions of B cell subsets
119 between HEU and HUU new-born babies, including, CD10⁻CD21⁺CD27⁻ (naive), CD10⁻
120 CD21⁻CD27⁺ (resting memory), CD10⁻CD21⁺CD27⁺ (activated memory), CD10⁻CD21⁻
121 CD27⁻ (tissue-like memory) and CD10⁺CD27⁻ (immature transitional) B cells (Figure 2a).
122 However, we found a higher proportion of Fc-receptor like 4 (FcRL4⁺) expressing B cells in
123 HEU new-borns, but no statistically significant differences in the proportion of PD-1 or
124 CD95-expressing B cells, when compared to HUU controls (Figure 2b). FcRL4⁺ inhibits B
125 cell activation through the B cell receptor (BCR) and is a marker of B cell exhaustion in
126 chronically HIV-infected adults⁶⁰, which suggests increased B cell regulation in HEU new-
127 born babies⁶¹.

128

129 In the T cell compartment, we found that the proportion of naïve and memory, CD4⁺ and
130 CD8⁺ T cell subsets were similar between HEU new-borns and HUU controls (Figure 3a-b).
131 There were also no differences between the two groups in the proportion of CD57 or PD-1-
132 expressing CD4⁺ and CD8⁺ T cells (Figure 3c-d), which are classical markers of T cell
133 immune senescence and exhaustion in chronic HIV infection^{62,63}. IFN γ production in
134 response to tuberculin purified protein derivative (PPD) in an 18-hour ELISpot assay was
135 similar in HEU new-borns compared to controls. In this population BCG is received soon
136 after birth. However, IFN γ production in response to the selective T cell mitogen
137 phytohemagglutinin (PHA)⁶⁴ was reduced in HEU new-borns compared to controls (figure
138 3e), indicating selective regulation of T-cell responses.

139

140 **Persistent dysregulation of the B cell compartment in HEU infants.**

141 Having found an altered innate compartment and increased regulatory B cell phenotype at
142 birth, we then investigated the impact of HIV exposure on adaptive immunity in the first few
143 months of life in the longitudinal infant cohort. We found that the proportions of immature
144 transitional and tissue-like memory B cells were lower in HEU infants than HUU controls
145 (Figure 4a), two B cell subsets that are selectively dysregulated in HIV infection ^{65,66}.

146 However, as seen in the new-born cohort, the proportions of naïve and memory, CD4+ and
147 CD8+ T cell subsets, were similar between HEU infants and HUU controls (Figure 4a-b).

148

149 **Increased IFN γ production to PPD in a T-cell ELISpot assay in HEU infants**

150 To determine if T-cell responses were altered in HEU infants, we evaluated IFN γ spot
151 forming cells (SFCs) to tetanus toxoid (TT), hepatitis B (Hb) and purified protein derivative
152 (PPD) in an 18-hour T-cell ELISpot in infants aged 5-9 weeks of age. We observed increased
153 IFN γ SFCs/million PBMCs to PPD amongst HEU infants compared to HUU controls, but
154 similar Hb, TT and PHA responses between the two groups (Supplementary figure 5a). These
155 data indicate that HEU infants' antigen-specific responses to PPD following BCG
156 vaccination at birth have the potential to be greater in capacity than HUU infants.

157

158 **Impaired IgG antibody responses to routine pentavalent vaccination in HEU infants.** In

159 the longitudinal infant cohort, having demonstrated B-cell dysregulation, we interrogated
160 vaccine-induced memory B cell antibody responses to polysaccharide and protein antigens
161 that are in the Malawian infant primary vaccination series. This included PCV13 and
162 Pentavalent Vaccine (DPT-HepB-Hib) which protect against several important infant disease-
163 causing bacteria, we focused on: *Streptococcus pneumoniae* (13 serotypes) and *Haemophilus*

164 *influenza* type b (Hib), *Clostridium tetani* (tetanus toxoid) and *Corynebacterium diphtheriae*
165 (diphtheria toxoid).

166

167 Following 3 vaccine doses, we found lower anti-*Hib* and anti-diphtheria toxoid (DT) titers,
168 but similar anti-TT titers in HEU infants, compared to HUU controls (Figure 5a-c). In the
169 mothers of these infants, anti-*Hib* IgG and anti-TT IgG titres but not anti-DT titers were
170 lower in HIV-infected mothers than HIV-uninfected controls (Figure 5d-f).

171 Having shown the B cell compartment produces differential antigen specific
172 immunoglobulins to vaccine antigens, we next tested whether HIV exposure influences the
173 levels of vaccine-induced functional antibody. Using a Multiplex
174 Opsonophagocytosis Assay (MOPA), we measured opsonophagocytic activity of 13 vaccine
175 serotypes from the PCV13 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in infant sera.
176 We found no difference in the geometric mean opsonophagocytic index (GMOI) of 13
177 pneumococcal serotypes and geometric mean concentration (GMC) of serotype-specific IgG
178 titres, between HEU infants and HUU controls (Table 2).

179

180 **Evidence of HIV exposure in early infancy**

181 Next, we sought to ascertain evidence of HIV exposure as a driver of dysregulation in innate
182 and adaptive immunity of HEU new-borns by measuring HIV specific responses from birth
183 to infancy. We measured HIV Gag-specific responses in peripheral blood mononuclear cells
184 ⁶⁷ using an 18-hour *ex-vivo* IFN- γ ELISpot assay in both the HEU new-born and the
185 longitudinal infant cohorts. (Figure 6a; Supplementary Figure 3a) ⁶⁸⁻⁷⁰. Few Gag-specific
186 responses were detectable in cord blood of HEU new-borns (Supplementary Figure 5).
187 Consistent with previous studies ^{71,72}, there was detectable IFN- γ producing HIV Gag-

188 specific cell responses in approximately 50% of the longitudinal cohort of HEU infants
189 (Figure 6b).

190

191 **HEU infants have increased exposure to maternal-derived hCMV**

192 HEU infants are more frequently exposed to human herpes viruses (HHV) *in utero* and/or
193 perinatally than HUU infants^{73,74}, due to the high seroprevalence and reactivation of hCMV
194 and EBV in HIV-infected individuals and pregnant women⁷⁵⁻⁸⁰. We therefore sought to
195 determine the extent of immune-modulating HHV, hCMV and EBV infection in our
196 longitudinal infant cohort.

197

198 We found that anti-hCMV IgG titers were higher in sera from HEU infants than HUU
199 controls (Figure 6c), but hCMV PCR detection was similar (Figure 6d), indicating potential
200 differences in the pattern of exposure to hCMV but not increased infection. We then
201 measured hCMV in maternal breastmilk as a potential source of transmission or transfer of
202 viral products to the infants. We found that the proportion of mothers with an hCMV positive
203 PCR result in breast milk was higher in the HIV-infected mothers compared to HIV-
204 uninfected controls (Figure 6e). In contrast, we did not observe any statistically significant
205 differences between potential EBV exposure in HEU infants compared to HUU controls,
206 whether by EBV IgG ELISA (Figure 6f) or PCR (Figure 6g). Overall, these results
207 demonstrate that HHV (hCMV and EBV) infection are common in infancy, irrespective of
208 HIV-exposure status. High hCMV titres in HEU infants may indicate immune boosting from
209 breastmilk of HIV-infected women.

210

211 **Discussion**

212 HIV-exposed but uninfected infants are at an increased risk of a wide variety of infections
213 even in the era of universal access to maternal ART, but the underlying immunological basis
214 is not well understood ^{7,51}. We show altered monocyte phagosomal function, dysregulated B
215 cell homeostasis and selective impairment of vaccine responses in HEU infants within the
216 first 6 months of life. We also demonstrate evidence of HIV exposure and increased
217 likelihood of hCMV exposure in HEU infants. HIV and hCMV are immunomodulatory
218 viruses ⁸¹, so co-exposure to these two pathogens in early life may contribute to this immune
219 dysregulation. We postulate that the complexity, variable severity and/or persistence of this
220 immunological phenotype explain the variable clinical manifestations reported in HEU
221 infants ^{8,9,11,40,82-86}, which may depend on the duration and intensity of exposure to HIV and
222 other infectious co-factors.

223

224 The impaired monocyte phagosomal function in HEU new-borns highlights their potential
225 vulnerability to bacterial infection before the primary immunisation series. Monocyte
226 bactericidal activity requires uptake, reactive oxygen species (ROS) formation and
227 phagosomes-lysosomes fusion resulting in inhibition, killing and degradation of internalised
228 bacteria ^{87,88}. In our setting, the validated flow cytometer reporter assay of phagocyte function
229 which uses zymosan has shown poor immune function and superoxide burst activity in HIV-
230 infected adults with active tuberculosis (TB)⁸⁹. Monocyte functional impairment against
231 encapsulated bacteria has also been observed in “age-associated” inflammation, where
232 monocyte-activating cytokines TNF- α and IL-6 are augmented ⁹⁰. Similarly, increased
233 monocyte inflammatory markers, including sTNF-RI, IL-6, IP-10, oxLDL and sCD14 are
234 reported in HEU new-borns ⁸⁷; as well as enhanced pro-inflammatory cytokine secretion
235 following stimulation with diverse PAMPs at 6 weeks of age ⁹¹. Moreover, recent PBMC
236 transcriptomic profiling in HEU infants at 1-2 years of age, revealed down-regulated genes

237 (LCN2, CAMP, HP, MMP8, BPI, LTF) associated with neutrophil function⁹². It is therefore
238 plausible that the observed impaired monocyte phagosomal function is a consequence of an
239 inflammatory microenvironment in HEU infants, from an inflammatory maternal cytokine
240 milieu and/or exposure to HIV antigens that could explain their increased susceptibility to
241 bacterial infection including pneumonia¹⁴.

242 In line with the proposed inflammatory environment in HEU new-borns⁹³, we observed high
243 proportions of FcLR4 expressing B cells. In HIV-infected adults, B cells expressing the
244 inhibitory receptor FcLR4 are over-represented, an ‘exhausted’ B cell phenotype, that
245 displays poor B cell receptor mediated activation and antigen-specific antibody production in
246 chronic HIV infection^{60,94,95}. Additionally, in HEU infants at 6 to 14 weeks of age, we
247 observed low proportions of tissue-like memory (TLM) and immature-transitional B-cell
248 subsets. TLM and immature transitional B cells are augmented in HIV-infected adults,
249 occurring most profoundly during chronic HIV infection^{96,97}. The contraction of atypical
250 memory B cells in HEU infants may be indicative of dysregulated B cell homeostasis⁹⁸.

251 Importantly, our data presents evidence of increased exposure to HIV and hCMV in HEU
252 infants from maternal HIV and/or viral proteins, hCMV recrudescence and high PPD specific
253 IFN γ , that may promote B cell dysregulation in the first 2 months of life. PPD responses are
254 shown to be increased in *mycobacterium tuberculosis* (Mtb) sensitised mothers, which may
255 explain our findings⁹⁹, furthermore, others have described a bimodal response to BCG/PPD
256 (high/low) in HEU infants in our setting¹⁰⁰. Taken together, the mechanisms of B cell
257 dysregulation are likely distinct from those seen in chronic HIV infection
258 (hypergammaglobulinaemia)¹⁰¹, due to the lack of replicative virus and preserved CD4 T-
259 cells.

260

261 Altered B cell homeostasis is associated with impaired antibody responses during chronic
262 HIV infection ^{102–105}. Consistent with this observation, HIV-infected mothers in our cohort
263 exhibited lower anti-Hib and anti-TT antibody titers than HIV-uninfected mothers. In
264 agreement with maternal titers, we observed low anti-Hib titers in HEU infants. It is known
265 that HIV-infected children are at greater risk of vaccine failure compared to HIV-uninfected
266 children ^{106–108}. However, our observation is in contrast with studies conducted in South
267 Africa ¹⁰⁹ and Uganda ^{110,111}, who reported robust anti-Hib and anti-DT antibody titers in
268 HEU infants. In our setting the Pentavalent Vaccine (DPT-HepB-Hib) was used, in South
269 Africa it was (DTP-Hib and DTaP-IPV/Hib) ¹⁰⁹, and in Uganda (aP-HibCV and
270 DTwP/HBV/PRP-T) ^{110,111}. Differential vaccine immunogenicity is likely multifactorial,
271 influenced by persistent immune exposure to HIV proteins, the time to maternal ART use and
272 the unique burden of infectious co-factors that likely contribute to a microenvironment of
273 pro-inflammation. Furthermore, HIV proteins are reported to cause aberrant binding to
274 surface immunoglobulins ^{112–115}, which may interfere with specific antibody responses.
275 Consistent with previous observations ¹¹⁶, we observed that a relatively large number of HEU
276 infants mounted an IFN- γ response following stimulation with HIV Gag, however we did not
277 detect IFN- γ responses in HEU new-borns. Detection of HIV-specific T cell responses in
278 HEU infants was first described nearly 30 years ago ^{71,72}. Others have reported that HEU
279 infants have increased regulatory T cells (Tregs) that correlate with decreased T cell function
280 ²⁹ and have shown that depletion of Treg cells from the cord blood of HEU new-borns reveals
281 HIV-1-specific T responses ¹¹⁶. We also observed poor IFN- γ responses in cord blood of
282 HEU new-borns following stimulation with the T cell mitogen PHA (which crosslinks the
283 TCR and glycosylated surface proteins). Taken together, these data point towards HIV
284 exposure as a possible driver of increased regulation/inhibition of T cell activation at birth.
285

286 Our study has some limitations, including use of a surrogate assay to measure monocyte
287 function and the limited number of assays we could perform on each sample. Additionally,
288 our cohorts were too small to establish direct associations with immune dysregulation and
289 clinical presentation of disease.

290

291 In conclusion, we show altered monocyte phagosomal function, dysregulated B cell
292 homeostasis and selective impairment of vaccine antibody responses in HEU infants within
293 the first 6 months of life. This period of vulnerability likely contributes to increased
294 susceptibility to disease-causing bacteria that commonly cause life-threatening illness such as
295 pneumonia in HEU infants.

296

297 **Methods**

298 **Study Design and population.** The study was conducted in Southern Malawi, at Ndirande
299 Health Centre (NHC) (a primary healthcare facility in the city of Blantyre) and at Queen
300 Elizabeth Central Hospital (QECH) (a tertiary teaching hospital in the city of Blantyre). We
301 recruited the infant cohort in two contiguous groups that were followed longitudinally. The
302 first group were aged 5-9 weeks (pre-1st vaccine dose) who were followed up to age 14-15
303 weeks (post-2nd vaccine dose) and the second group were aged 14-15 weeks (post-2nd vaccine
304 dose) who were followed up to 18-23 weeks of age (post-3rd vaccine dose). We recruited
305 pregnant women in the early stages of labour at QECH maternity ward and subsequently their
306 babies at birth (termed birth cohort). Participating mothers were healthy, asymptomatic adults
307 (>18 yr) comprising HIV-infected and HIV-uninfected volunteers. HIV testing was
308 performed on whole blood using two commercial point-of-care rapid HIV test kits,
309 Determine HIV 1/2 kit (Abbott Diagnostic Division, Abbott Park, IL) and Unigold HIV 1/2
310 kit (Trinity Biotech Inc., Bray, Ireland). HIV-infected participants received first line ART

311 (Option B+ (Lamivudine, Tenofovir DF and Efavirenz (3TC/TDF/EFV)) at any point during
312 pregnancy and had a CD4+ T-cell count performed. All HEU babies received single dose
313 nevirapine at birth and co-trimoxazole until 6 months of age. Exclusion criteria for the study
314 participants were current or past history of smoking, heart disease, tuberculosis, high blood
315 pressure, drug use, syphilis, severe anaemia (haemoglobin <8 g/dl), placental abnormalities,
316 infant death and existing comorbidities. All babies received Bacille Calmette Guerin (BCG)
317 vaccine at birth. Written informed consent was obtained from all participants prior to
318 recruitment. Ethical approval was obtained from the University of Malawi College of
319 Medicine Research and ethics committee (COMREC), Blantyre, Malawi, protocol numbers
320 P.11/11/1140, P.06/11/1088.

321

322 **Sample collection and processing.** To maximise the number of samples we were able to
323 collect from very young infants, we collected 5ml of venous blood from the infants, at 5-9,
324 14-15 and 18-23 weeks of age following attendance at the vaccination clinic for pentavalent
325 DPT-HepB-Hib immunisation. Participants who did not complete their vaccine course were
326 excluded from the analysis. From their mothers, 10ml of venous blood were collected only at
327 the first visit and 3mls of breastmilk at all three time points. We collected up to 40ml cord
328 blood from the umbilical vein into sodium heparinised tubes using a 50ml syringe from the
329 baby interface of the placenta immediately after birth. Whole blood was kept at RT for no
330 longer than 2 hours from collection to processing. Peripheral blood mononuclear cells were
331 isolated by density centrifugation. Diluted whole blood was layered on top of Histopaque
332 Ficoll gradient (Sigma-Aldrich, UK) at a ratio of 2:1 and centrifuged (900g, 24 °C for 30
333 minutes). The PBMC fraction was removed using a Pasteur pipette and washed immediately
334 in HBSS (Sigma Aldrich, UK) by centrifugation (500g, 4 °C for 5 minutes). Cells were re-
335 suspended in 2mL of complete media ((RPMI 1640 plus (Sigma-Aldrich, UK) with 10mM

336 HEPES (Sigma-Aldrich, UK), 1% v/v penicillin, 1% V/V streptomycin (Sigma Aldrich) and
337 2mM L-glutamine (Sigma-Aldrich, UK)), then agitated to ensure complete mixing and
338 counted using a haemocytometer with 1:10 trypan blue (Sigma Aldrich, UK) staining to
339 confirm viability. Plasma was separated by centrifugation at 1500rpm for 10 minutes,
340 aspirated, aliquoted and stored at -80 for later use. Breastmilk samples were collected by
341 hand expression, fractionated into lipid and aqueous phase and stored at -80. Due to
342 limitations in the volume of blood collectable from very young babies and limited cell
343 numbers, not all the assays were performed on samples obtained from every participant.

344

345 **HIV testing.** New-borns and infants qualitative HIV DNA PCR tests were performed in
346 batches of 23. Total RNA was isolated from 0.5×10^6 cells using AMPLICOR HIV-1 DNA
347 test, V1.5 (Roche, USA) according to the manufacturer's instructions.

348 Three HIV-RDT kits, from two separate manufacturers (Unigold™ and Determine™) were
349 used to confirm the presence or absence of HIV specific immunoglobulins (Ig) in maternal
350 peripheral blood. Cord blood mononuclear cells (CBMCs) from were stored in 500ul of
351 RNAlater and analysed at UCL by digital PCR as described elsewhere ¹¹⁷.

352

353 **Maternal CD4 counts.** Peripheral blood CD4 T-counts and full blood count (FBC) were
354 performed at the Malawi-Liverpool Wellcome Trust Clinical Research Programme
355 Diagnostic Laboratory on an Hmx analyser (Beckman Coulter, USA) using a standardized
356 protocol.

357

358 **Phenotypic analysis.** Multicolour flow cytometry analysis was performed on whole blood
359 (WB). Samples were stained with the following fluorochrome conjugated antibodies, anti-
360 CD14 Phycoerythrin Cyanine-7 (PECy7), anti-CD3 Allophycocyanin-H7 (APC-H7), anti-

361 CD4 Pacific Blue (PB), anti-CD8 Fluorescein (FITC), anti-CD8 (PECY7), CD45RA
362 Phycoerythrin (PE), CD45RA PECY5, CCR7 Allophycocyanin (APC), anti-CD19 (APC),
363 anti-CD19 Peridinin-Chlorophyll-Protein (PERCP), anti-CD27 (PE), , CD10 PE-Cy7, CD21
364 FITC, CD27 APC-Cy7, CD95 e450, FcLR4 PE, CD57 FITC, PD-1 APC, PD-1 PE
365 (Supplementary Tables 1 and 2, Gating strategy supplementary figure 2). Samples were
366 acquired on Beckman Coulter Cyan ADP and analyses were performed using FlowJo Version
367 7.6.5 and 10.5 software (Treestar).

368

369 **Measurement of monocyte phagosomal enzymatic activity.** Phagosomal oxidative burst
370 and bulk proteolytic function in monocytes was measured using a flow cytometry–based
371 reporter bead assay as described previously^{57,118,119}. Briefly, 3µm diameter silica beads were
372 derivatized with the calibration fluorochrome (Alexa Fluor 405-SE) and the fluorogenic
373 reporter substrates Oxyburst Green succinimidyl ester (Oxybeads) (Molecular Probes,
374 Eugene, OR) for superoxide burst, or DQ Green bovine serum albumin (DQ-beads)
375 (Molecular Probes, Eugene, OR) for bulk proteolysis. When the beads are internalised by
376 monocytes the fluorescence intensity is proportional to the degree of activity in the
377 phagosome, which provided a readout of phagosomal enzymatic activity. The readout for the
378 assay is reported as the ratio of the median fluorescent intensity of the reporter fluorochrome
379 at 60mins:10mins and 240mins:10mins for oxidative burst and bulk proteolysis, respectively.
380 The uptake cut-off was 35% in the assay.

381

382 **T cell IFN γ ELISpot.** 2x10⁶ PBMCs were stimulated in an 18-hour IFN- γ T cell ELISpot;
383 plates were coated with purified anti-human interferon- γ monoclonal antibody (α human-
384 IFN- γ -mAb) 1-D1K (Mabtech, UK) 1:66 at a concentration of 3.78µg/mL in sterile PBS. The
385 enumerated IFN- γ producing cells after antigen stimulation were used as an index of effector

386 memory T cell responses, as previously described ¹²⁰. Data were reported after deducting 2x
387 the value of the negative well. Stimulating antigens were: Phaseolus vulgaris lectin (PHA)
388 5ug/ml (NIBSC, UK), purified protein derivative (PPD) 10ug/ml (Statens serum institute,
389 Denmark) and HIV-1 consensus C gag 15-mer peptides (GAG peptide) 10ug/ml (NIH AIDS,
390 USA)¹²⁰

391

392 **Human cytomegalovirus PCR** . Real time PCR was used to detect hCMV in HIV-infected
393 and uninfected maternal breast milk and plasma. The results were based on a standard curve
394 constructed using an in-house plasmid previously calibrated against quality controls for
395 molecular diagnostics and external quality assessment panels (Hamprecht et al. 1998). The
396 positive control was assessed again and an expected value of 2,500 copies seen with results
397 read on the ABI Prism 7500 (Thermofisher, UK). The amplification plot was assessed against
398 a standard slope range of -3.10 to -3.60 and a R² value > 0.9.

399

400 **Detection of Cytomegalovirus specific IgG and IgM antibodies.** hCMV specific IgM in
401 plasma was measured using a commercial ELISA kit (IBL International, Hamburg) according
402 to manufacturer's instructions. A semi-quantitative, in-house hCMV IgG assay was used at
403 the laboratories in the University of Birmingham, UK. Plasma was diluted 1/4 in a dilution in
404 a 1:1:1 mix of plasma from three healthy donors, the top concentration was assigned an
405 arbitrary unit of 1000. The unknown samples were related to the standard curve and a titre
406 calculated. Briefly, Nunc 96-well plates Maxisorb (Fisher Scientific # 442404) were coated
407 with 50µL UV activated hCMV-lysate (1:4000) and mock-lysate (1:4000) in carbonate-
408 bicarbonate buffer pH 9.6 (sigma capsules), then covered with parafilm and incubated at 4°C
409 overnight in the fridge. The following day, plates were washed three times in 200µL (PBS +
410 0.05% Tween20), 100µL of samples were added 1:600 in dilution buffer (PBS + 1%BSA +

411 0.05% Tween20), blank dilution buffer, and standards, then incubated for 1h at room
412 temperature (RT). Plates were washed again three times, then 100µL of the secondary
413 antibody, anti-human IgG-HRP (1/8000 dilution in PBS+1% BSA+0.05% Tween20) goat
414 anti- human IgG (Southern Biotech #2040-05). Plates were incubated and washed again as
415 described, after which 100µL of tetramethyl benzidine (TMB-solution) (Tebu-Bio) was added
416 for 10 min at RT. The reaction was stopped with 100µL 1M HCl and plates were read at
417 405nm (Biotek instrument).

418

419 **Sandwich enzyme-linked immunosorbent assay to detect IgG specific to vaccine**

420 **antigens.** In an in-house ELISA, TT or DT (both NIBSC, UK) were diluted to 0.5 Lf/mL or
421 Hib capsular polysaccharide 0.1µg/mL in 10 mL carbonate coating buffer (0.015 M Na₂CO₃,
422 0.035 M NaHCO₃ pH9.6); 100 µL per well of the solution was pipetted into a 96-well flat
423 bottom Maxisorp plate. Plates were incubated overnight at 4 °C then washed seven times with
424 PBS 0.05% Tween. 50 µl goat anti-human alkaline phosphatase-conjugated secondary
425 antibodies (Southern Biotech, UK) were diluted to 1ug/mL in PBS 0.05% Tween 2% BSA
426 and added to each well. The plates were incubated for 1 h at 37 °C, then washed seven times
427 with PBS 0.05% Tween. 100 µL of Sigma-fast p-nitrophenyl phosphate substrate was added
428 to each well (Sigma, UK). A standard curve was generated using a set of 2- fold dilutions of a
429 standard pooled serum (NIBSC, UK). Optical density was measured (without acid stopping
430 the reaction) after 10 min using an ELISA plate reader (Biotek, UK) set at 405nm and
431 SoftMax Pro software ¹²¹.

432

433 **Multiplexed opsonophagocytosis killing assay and serotype-specific IgG .** Sera from 20

434 infants were sent on dry ice to the UCL Great Ormond Street Institute of Child Health (UCL;
435 United Kingdom). Infants had received 3 doses of Prevnar (PCV13) at 6, 10, and 14 weeks of

436 age. Sera were stored at -20°C until analysis. Analyses were performed at the World Health
437 Organization pneumococcal reference laboratory (University College London, United
438 Kingdom). Immunoglobulin G (IgG) serum concentrations specific for the 13 vaccine
439 serotypes (1, 3, 4, 5, 6 A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were measured using an
440 enzyme-linked immunosorbent assay (ELISA) after adsorption with cell-wall and 22F
441 polysaccharides to increase the assay specificity¹²². A standardized opsonophagocytic assay
442 (OPA) was used to measure functional antibodies against the same serotypes¹²³. The OPA
443 titre was defined as the reciprocal of the lowest serum dilution that induces $\geq 50\%$ bacterial
444 cell death compared to the assay control.

445

446 **Statistical analysis.** Statistical analysis and graphical presentation were performed using
447 Prism 7/8 (GraphPad Software, San Diego, USA) and Python (Python Software Foundation)
448 was used to calculate summary statistics. Demographic and clinical characteristics were
449 compared using Mann-Whitney-U for continuous and Fisher's exact tests or χ^2 for discrete
450 variables. ELISpot data were reported as subtracted 2 x background. Serotype-specific
451 opsonophagocytic indexes (OIs) were reported using geometric means and 95% confidence
452 intervals. The OIs were classified as being positive or negative based on the current
453 recommended cut-off value of < 8 (negative) and ≥ 8 (positive). Results are reported as
454 median and IQR as stated.

455

456 **Acknowledgments**

457 The authors are grateful to the participants for their willingness to participate in this study.
458 This work was supported by a studentship from the Franklin Adams Trust and a project grant
459 from the Wellcome Trust . The Malawi-Liverpool-Wellcome Trust Clinical Research
460 Programme was supported by a strategic award from the Wellcome Trust.

461

462 **Author contribution**

463 L.A, A.F, R.S.H, S.R.J, D.M contributed to study design. L.A, A.B, B.F, R.K, D.H.B, D.G,

464 P.M, D.M performed the experiments. W.N recruited and monitored the participants. L.A,

465 K.C.J analysis and interpretation. H.M, D.M, A.F., K.C.J, R.S.H, reviewing the manuscript

466 L.A, K.C.J, S.R.J, A.F, R.S.H, final approval.

467

468 **Competing interests**

469 The authors declare no competing interests.

470

471 **References**

- 472 1. Afran, L. *et al.* HIV-exposed uninfected children: a growing population with a
473 vulnerable immune system? *Clin. Exp. Immunol.* **176**, 11–22 (2014).
- 474 2. le Roux, S. M. *et al.* Infectious morbidity of breastfed, HIV-exposed uninfected infants
475 under conditions of universal antiretroviral therapy in South Africa: a prospective
476 cohort study. *Lancet Child Adolesc. Heal.* **4**, 220–231 (2020).
- 477 3. Slogrove, A. L., Goetghebuer, T., Cotton, M. F., Singer, J. & Bettinger, J. A. Pattern of
478 Infectious Morbidity in HIV-Exposed Uninfected Infants and Children. *Front.*
479 *Immunol.* **7**, 164 (2016).
- 480 4. Gompels, U. A. *et al.* Human Cytomegalovirus Infant Infection Adversely Affects
481 Growth and Development in Maternally HIV-Exposed and Unexposed Infants in
482 Zambia. *Clin. Infect. Dis.* **54**, 434–42 (2012).
- 483 5. Slyker, J. A. *et al.* The detection of cytomegalovirus DNA in maternal plasma is
484 associated with mortality in HIV-1-infected women and their infants. *AIDS January*
485 **23**, 117–124 (2009).
- 486 6. Slyker, J. A. *et al.* Acute cytomegalovirus infection in Kenyan HIV-infected infants.
487 *AIDS* **23**, 2173–81 (2009).
- 488 7. Dauby, N., Chamekh, M., Melin, P., Slogrove, A. L. & Goetghebuer, T. Increased
489 Risk of Group B Streptococcus Invasive Infection in HIV-Exposed but Uninfected
490 Infants: A Review of the Evidence and Possible Mechanisms. *Front. Immunol.* **7**, 505
491 (2016).
- 492 8. Izadnegahdar, R., Fox, M. P., Jeena, P., Qazi, S. A. & Thea, D. M. Revisiting
493 pneumonia and exposure status in infants born to HIV-infected mothers. *Pediatr.*
494 *Infect. Dis. J.* **33**, 70–2 (2014).

- 495 9. Adler, C. *et al.* Severe Infections in HIV-Exposed Uninfected Infants Born in a
496 European Country. *PLoS One* **10**, e0135375 (2015).
- 497 10. Slogrove, A. L., Cotton, M. F. & Esser, M. M. Severe Infections in HIV-Exposed
498 Uninfected Infants: Clinical Evidence of Immunodeficiency. *J. Trop. Pediatr.* **56**, 75–
499 81 (2010).
- 500 11. Slogrove, A. *et al.* HIV-Exposed Uninfected Infants are at Increased Risk for Severe
501 Infections in the First Year of Life. *J. Trop. Pediatr.* **58**, 505–508 (2012).
- 502 12. McNally, L. M. *et al.* Effect of age, polymicrobial disease, and maternal HIV status on
503 treatment response and cause of severe pneumonia in South African children: a
504 prospective descriptive study. *Lancet* **369**, 1440–1451 (2007).
- 505 13. Kelly, M. S. *et al.* Treatment Failures and Excess Mortality Among HIV-Exposed,
506 Uninfected Children With Pneumonia. *J. Pediatric Infect. Dis. Soc.* **4**, e117-26 (2015).
- 507 14. Brennan, A. T. *et al.* A Meta-analysis Assessing Diarrhea and Pneumonia in HIV-
508 Exposed Uninfected Compared with HIV-Unexposed Uninfected Infants and Children.
509 *Journal of Acquired Immune Deficiency Syndromes* **82**, 1–8 (2019).
- 510 15. Singh, H. K. *et al.* High Rates of All-cause and Gastroenteritis-related Hospitalization
511 Morbidity and Mortality among HIV-exposed Indian Infants. *BMC Infect. Dis.* **11**, 193
512 (2011).
- 513 16. UNAIDS. Joint United Nations Programme on HIV/AIDS. (2019). Available at:
514 <https://www.unaids.org/en/resources/documents/2019/2019-UNAIDS-data>. (Accessed:
515 31st December 2020)
- 516 17. South, A. *et al.* Estimates of the global population of children who are HIV-exposed
517 and uninfected, 2000-18: a modelling study. *Artic. Lancet Glob Heal.* **8**, 67–75 (2020).
- 518 18. Sevenoaks, T. *et al.* Association of maternal and infant inflammation with

- 519 neurodevelopment in HIV-exposed uninfected children in a South African birth cohort.
520 *Brain. Behav. Immun.* (2020). doi:10.1016/j.bbi.2020.08.021
- 521 19. Goetghebuer, T. *et al.* Initiation of Antiretroviral Therapy Before Pregnancy Reduces
522 the Risk of Infection-related Hospitalization in Human Immunodeficiency Virus-
523 exposed Uninfected Infants Born in a High-income Country. *Clin. Infect. Dis.* **68**,
524 1193–1203 (2019).
- 525 20. Van Dyke, R. B., Chadwick, E. G., Hazra, R., Williams, P. L. & Seage, G. R. The
526 PHACS SMARTT Study: Assessment of the Safety of In Utero Exposure to
527 Antiretroviral Drugs. *Front. Immunol.* **7**, 23 (2016).
- 528 21. D’Souza, A. W. *et al.* Cotrimoxazole prophylaxis increases resistance gene prevalence
529 and α -diversity but decreases β -diversity in the gut microbiome of HIV-exposed,
530 uninfected infants. *Clin. Infect. Dis.* (2019). doi:10.1093/cid/ciz1186
- 531 22. Goetghebuer, T., Rowland-Jones, S. L. & Kollmann, T. R. Editorial: Immune
532 Mechanisms Underlying the Increased Morbidity and Mortality of HIV-Exposed
533 Uninfected (HEU) Children. *Front. Immunol.* **8**, 1060 (2017).
- 534 23. de Deus, N. *et al.* Impact of elevated maternal HIV viral load at delivery on T-cell
535 populations in HIV exposed uninfected infants in Mozambique. *BMC Infect. Dis.* **15**,
536 37 (2015).
- 537 24. Longwe, H. *et al.* Proportions of CD4+, CD8+ and B cell subsets are not affected by
538 exposure to HIV or to Cotrimoxazole prophylaxis in Malawian HIV-uninfected but
539 exposed children. *BMC Immunol.* **16**, 50 (2015).
- 540 25. Kakkar, F. *et al.* Impact of maternal HIV-1 viremia on lymphocyte subsets among
541 HIV-exposed uninfected infants: protective mechanism or immunodeficiency. *BMC*
542 *Infect. Dis.* **14**, 236 (2014).

- 543 26. Kidzeru, E. B. *et al.* In-utero exposure to maternal HIV infection alters T-cell immune
544 responses to vaccination in HIV-uninfected infants. *AIDS* **28**, 1421–30 (2014).
- 545 27. Bunders, M. J. *et al.* Fetal exposure to HIV-1 alters chemokine receptor expression by
546 CD4+T cells and increases susceptibility to HIV-1. *Sci. Rep.* **4**, 6690 (2014).
- 547 28. Gabriel, B. *et al.* Analysis of the TCR Repertoire in HIV-Exposed but Uninfected
548 Infants. *Sci. Rep.* **9**, (2019).
- 549 29. Jalbert, E. *et al.* HIV-exposed uninfected infants have increased regulatory T cells that
550 correlate with decreased T cell function. *Front. Immunol.* **10**, (2019).
- 551 30. Nduati, E. W. *et al.* HIV-Exposed Uninfected Infants Show Robust Memory B-Cell
552 Responses in Spite of a Delayed Accumulation of Memory B Cells: an Observational
553 Study in the First 2 Years of Life. *Clin. Vaccine Immunol.* **23**, 576–85 (2016).
- 554 31. Mazzola, T. N. *et al.* Impaired Bacillus Calmette-Guérin cellular immune response in
555 HIV-exposed, uninfected infants. *AIDS* **25**, 2079–87 (2011).
- 556 32. Abramczuk, B. M. *et al.* Impaired Humoral Response to Vaccines among HIV-
557 Exposed Uninfected Infants. *Clin. Vaccine Immunol.* **18**, 1406–1409 (2011).
- 558 33. Reikie, B. A. *et al.* Antibody Responses to Vaccination among South African HIV-
559 Exposed and Unexposed Uninfected Infants during the First 2 Years of Life. *Clin.*
560 *Vaccine Immunol.* **20**, 33–38 (2013).
- 561 34. Gasper, M. A. *et al.* Natural killer cell and T-cell subset distributions and activation
562 influence susceptibility to perinatal HIV-1 infection. *AIDS* **28**, 1115–24 (2014).
- 563 35. Simani, O. E. *et al.* Effect of in-utero HIV exposure and antiretroviral treatment
564 strategies on measles susceptibility and immunogenicity of measles vaccine. *AIDS* **27**,
565 1583–1591 (2013).

- 566 36. Bunders, M. J. *et al.* Haematological parameters of HIV-1-uninfected infants born to
567 HIV-1-infected mothers. *Acta Paediatrica* **94**, 1571–1577 (2005).
- 568 37. Reikie, B. A. *et al.* Altered innate immune development in HIV-exposed uninfected
569 infants. *J. Acquir. Immune Defic. Syndr.* **66**, 245–55 (2014).
- 570 38. Evans, C. *et al.* CMV acquisition and inflammation in HIV-exposed uninfected
571 Zimbabwean infants. *J. Infect. Dis.* **215**, jiw630 (2016).
- 572 39. Montoya-Ferrer, A. *et al.* Clinical and Biological Factors Associated With Early
573 Epstein-Barr Virus Infection in Human Immunodeficiency Virus–Exposed Uninfected
574 Infants in Eastern Uganda. *Clin. Infect. Dis.* (2020). doi:10.1093/cid/ciaa161
- 575 40. Wedderburn, C. J. *et al.* Growth and Neurodevelopment of HIV-Exposed Uninfected
576 Children: a Conceptual Framework. *Current HIV/AIDS Reports* **16**, 501–513 (2019).
- 577 41. Evans, C. *et al.* Inflammation, cytomegalovirus and the growth hormone axis in HIV-
578 exposed uninfected Zimbabwean infants. *AIDS* (2020).
579 doi:10.1097/QAD.0000000000002646
- 580 42. Jao, J. *et al.* Lower mitochondrial DNA and altered mitochondrial fuel metabolism in
581 HIV-exposed uninfected infants in Cameroon. *AIDS* **31**, 2475–2481 (2017).
- 582 43. Filteau, S. & Rowland-Jones, S. Cytomegalovirus infection may contribute to the
583 reduced immune function, growth, development, and health of HIV-exposed,
584 uninfected African children. *Frontiers in Immunology* **7**, 257 (2016).
- 585 44. Garcia-Knight, M. A. *et al.* Cytomegalovirus viraemia is associated with poor growth
586 and T-cell activation with an increased burden in HIV-exposed uninfected infants.
587 *AIDS* **31**, 1809–1818 (2017).
- 588 45. WHO, G. program on A. *PREVENT HIV, TEST AND TREAT ALL WHO SUPPORT*
589 *FOR COUNTRY IMPACT.* (2016).

- 590 46. Mendez-Lopez, A. *et al.* Population uptake and effectiveness of test-and-treat
591 antiretroviral therapy guidelines for preventing the global spread of HIV: an ecological
592 cross-national analysis. *HIV Med.* **20**, 501–512 (2019).
- 593 47. Arikawa, S., Rollins, N., Newell, M.-L. & Becquet, R. Mortality risk and associated
594 factors in HIV-exposed, uninfected children. *Trop. Med. Int. Heal.* **21**, 720–734
595 (2016).
- 596 48. Brennan, A. T. *et al.* A meta-analysis assessing all-cause mortality in HIV-exposed
597 uninfected compared with HIV-unexposed uninfected infants and children. *AIDS* **30**,
598 2351–60 (2016).
- 599 49. Epalza, C. *et al.* High Incidence of Invasive Group B Streptococcal Infections in HIV-
600 Exposed Uninfected Infants. *Pediatrics* **126**, e631–e638 (2010).
- 601 50. Cools, P. *et al.* Role of HIV exposure and infection in relation to neonatal GBS disease
602 and rectovaginal GBS carriage: a systematic review and meta-analysis. *Sci. Rep.* **7**,
603 13820 (2017).
- 604 51. Taron-Brocard, C. *et al.* Increased risk of serious bacterial infections due to maternal
605 immunosuppression in HIV-exposed uninfected infants in a European country. *Clin.*
606 *Infect. Dis.* **59**, 1332–45 (2014).
- 607 52. Prosser, A. *et al.* Phagocytosis of neonatal pathogens by peripheral blood neutrophils
608 and monocytes from new-born preterm and term infants. *Pediatr. Res.* **74**, 503–510
609 (2013).
- 610 53. Wong, K. L. *et al.* The three human monocyte subsets: Implications for health and
611 disease. *Immunol. Res.* **53**, 41–57 (2012).
- 612 54. Olliver, M., Hiew, J., Mellroth, P., Henriques-Normark, B. & Bergman, P. Human
613 Monocytes Promote Th1 and Th17 Responses to *Streptococcus pneumoniae*. *Infect.*

- 614 *Immun.* **79**, 4210–4217 (2011).
- 615 55. Goto, Y. *et al.* Monocyte recruitment into the lungs in pneumococcal pneumonia. *Am.*
616 *J. Respir. Cell Mol. Biol.* **30**, 620–626 (2004).
- 617 56. Serbina, N. V., Jia, T., Hohl, T. M. & Pamer, E. G. Monocyte-mediated defense
618 against microbial pathogens. *Annual Review of Immunology* **26**, 421–452 (2008).
- 619 57. Jambo, K. C. *et al.* Small alveolar macrophages are infected preferentially by HIV and
620 exhibit impaired phagocytic function. *Mucosal Immunol.* (2014).
621 doi:10.1038/mi.2013.127
- 622 58. Serbina, N. V., Jia, T., Hohl, T. M. & Pamer, E. G. Monocyte-Mediated Defense
623 Against Microbial Pathogens. *Annu. Rev. Immunol.* **26**, 421–452 (2008).
- 624 59. Jutras, I. & Desjardins, M. Phagocytosis: At the Crossroads of Innate and Adaptive
625 Immunity. *annualreviews.org* **21**, 511–527 (2005).
- 626 60. Kardava, L. *et al.* Attenuation of HIV-associated human B cell exhaustion by siRNA
627 downregulation of inhibitory receptors. *J. Clin. Invest.* **121**, 2614–2624 (2011).
- 628 61. Musimbi, Z. D. *et al.* Peripheral blood mononuclear cell transcriptomes reveal an over-
629 representation of down-regulated genes associated with immunity in HIV-exposed
630 uninfected infants. *Sci. Rep.* **9**, (2019).
- 631 62. Petrovas, C. *et al.* Differential association of programmed death-1 and CD57 with ex
632 vivo survival of CD8+ T cells in HIV infection. *J. Immunol.* **183**, 1120–32 (2009).
- 633 63. Landay, D. E. N. and A. L. Biomarkers of immune dysfunction in HIV. *curr opin hiv*
634 *aids* **5**, 175–180 (2013).
- 635 64. Abolfazl Movafagh, Heydary, H., Mortazavi-Tabatabaei, S. A. & Azargashb, E. The
636 Significance Application of Indigenous Phytohemagglutinin (PHA) Mitogen on

- 637 Metaphase and Cell Culture Procedure - PubMed. *Iran j pharm res* (2011). Available
638 at: <https://pubmed.ncbi.nlm.nih.gov/24250428/>. (Accessed: 17th November 2020)
- 639 65. Sciaranghella, G., Tong, N., Mahan, A. E., Suscovich, T. J. & Alter, G. Decoupling
640 activation and exhaustion of B cells in spontaneous controllers of HIV infection. *AIDS*
641 **27**, 175–80 (2013).
- 642 66. Ho, J. *et al.* Two overrepresented B cell populations in HIV-infected individuals
643 undergo apoptosis by different mechanisms. *Proc. Natl. Acad. Sci. U. S. A.* **103**,
644 19436–41 (2006).
- 645 67. Cox, J. H., Ferrari, G. & Janetzki, S. Measurement of cytokine release at the single cell
646 level using the ELISPOT assay. *Methods* **38**, 274–282 (2006).
- 647 68. Karlsson, A. C. *et al.* Comparison of the ELISPOT and cytokine flow cytometry
648 assays for the enumeration of antigen-specific T cells. *J. Immunol. Methods* **283**, 141–
649 153 (2003).
- 650 69. Tassignon, J. *et al.* Monitoring of cellular responses after vaccination against tetanus
651 toxoid: Comparison of the measurement of IFN- γ production by ELISA, ELISPOT,
652 flow cytometry and real-time PCR. *J. Immunol. Methods* **305**, 188–198 (2005).
- 653 70. Meierhoff, G., Ott, P. A., Lehmann, P. V. & Schloot, N. C. Cytokine detection by
654 ELISPOT: Relevance for immunological studies in type 1 diabetes.
655 *Diabetes/Metabolism Research and Reviews* **18**, 367–380 (2002).
- 656 71. Rowland-Jones, S. L. L. *et al.* HIV-specific cytotoxic T-cell activity in an HIV-
657 exposed but uninfected infant. *Lancet* **341**, 860–861 (1993).
- 658 72. Cheynier, R. *et al.* Cytotoxic T lymphocyte responses in the peripheral blood of
659 children born to human immunodeficiency virus-1-infected mothers. *Eur. J. Immunol.*
660 **22**, 2211–2217 (1992).

- 661 73. Adachi, K. *et al.* Cytomegalovirus Urinary Shedding in HIV-infected Pregnant
662 Women and Congenital Cytomegalovirus Infection. *Clin. Infect. Dis.* **65**, 405–413
663 (2017).
- 664 74. Adachi, K. *et al.* Congenital Cytomegalovirus and HIV Perinatal Transmission.
665 *Pediatr. Infect. Dis. J.* **37**, 1016–1021 (2018).
- 666 75. Miles, D. J. C. *et al.* Cytomegalovirus Infection in Gambian Infants Leads to Profound
667 CD8 T-Cell Differentiation. *J. Virol.* **81**, 5766–5776 (2007).
- 668 76. Kaye, S. *et al.* Virological and Immunological Correlates of Mother-to-Child
669 Transmission of Cytomegalovirus in The Gambia. *J. Infect. Dis.* **197**, 1307–1314
670 (2008).
- 671 77. Mutalima, N. *et al.* Associations between Burkitt lymphoma among children in
672 Malawi and infection with HIV, EBV and malaria: Results from a case-control study.
673 *PLoS One* **3**, (2008).
- 674 78. Schaftenaar, E. *et al.* High seroprevalence of human herpesviruses in HIV-infected
675 individuals attending primary healthcare facilities in rural South Africa. *PLoS One* **9**,
676 e99243 (2014).
- 677 79. Piriou, E. *et al.* Early age at time of primary Epstein-Barr virus infection results in
678 poorly controlled viral infection in infants from Western Kenya: clues to the etiology
679 of endemic Burkitt lymphoma. *J. Infect. Dis.* **205**, 906–13 (2012).
- 680 80. Purtilo, D. T. & Sakamoto, K. Reactivation of Epstein-Barr virus in pregnant women:
681 social factors, and immune competence as determinants of lymphoproliferative
682 diseases-a hypothesis. *Med. Hypotheses* **8**, 401–8 (1982).
- 683 81. Kourtis, A. P. *et al.* Cytomegalovirus IgG Level and Avidity in Breastfeeding Infants
684 of HIV-Infected Mothers in Malawi. *Clin. Vaccine Immunol.* **22**, 1222–1226 (2015).

- 685 82. Deichsel, E. L. *et al.* Birth size and early pneumonia predict linear growth among HIV-
686 exposed uninfected infants. *Matern. Child Nutr.* **15**, (2019).
- 687 83. Chaudhury, S. *et al.* Neurodevelopment of HIV-Exposed and HIV-Unexposed
688 Uninfected Children at 24 Months. *Pediatrics* **140**, (2017).
- 689 84. Slogrove, A. L. *et al.* Surviving and Thriving-Shifting the Public Health Response to
690 HIV-Exposed Uninfected Children: Report of the 3rd HIV-Exposed Uninfected Child
691 Workshop. *Front. Pediatr.* **6**, 157 (2018).
- 692 85. Zash, R. *et al.* HIV-exposed children account for more than half of 24-month mortality
693 in Botswana. *BMC Pediatr.* **16**, (2016).
- 694 86. Liu, H. *et al.* Characterization of human respiratory syncytial virus (RSV) isolated
695 from HIV-exposed-uninfected and HIV-unexposed infants in South Africa during
696 2015-2017. *Influenza Other Respi. Viruses* **14**, 403–411 (2020).
- 697 87. Amer, A. O. & Swanson, M. S. A phagosome of one's own: A microbial guide to life
698 in the macrophage. *Current Opinion in Microbiology* **5**, 56–61 (2002).
- 699 88. Fang, F. C. Antimicrobial reactive oxygen and nitrogen species: Concepts and
700 controversies. *Nature Reviews Microbiology* **2**, 820–832 (2004).
- 701 89. Gupta-Wright, A. *et al.* Functional Analysis of Phagocyte Activity in Whole Blood
702 from HIV/Tuberculosis-Infected Individuals Using a Novel Flow Cytometry-Based
703 Assay. *Front. Immunol.* **8**, 1222 (2017).
- 704 90. Puchta, A. *et al.* TNF Drives Monocyte Dysfunction with Age and Results in Impaired
705 Anti-pneumococcal Immunity. *PLOS Pathog.* **12**, e1005368 (2016).
- 706 91. Reikie, B. A. *et al.* Altered innate immune development in HIV-exposed uninfected
707 infants. *J. Acquir. Immune Defic. Syndr.* **66**, 245–55 (2014).

- 708 92. Musimbi, Z. D. *et al.* Peripheral blood mononuclear cell transcriptomes reveal an over-
709 representation of down-regulated genes associated with immunity in HIV-exposed
710 uninfected infants. *Sci. Rep.* **9**, (2019).
- 711 93. Dirajlal-Fargo, S. *et al.* HIV-exposed-uninfected infants have increased inflammation
712 and monocyte activation. *AIDS* **33**, 845–853 (2019).
- 713 94. Ehrhardt, G. R. A. *et al.* Discriminating gene expression profiles of memory B cell
714 subpopulations. *J. Exp. Med.* **205**, 1807–1817 (2008).
- 715 95. Moir, S. & Fauci, A. S. Insights Into B Cells And Hiv-Specific B-Cell Responses In
716 Hiv-Infected Individuals. *Immunol. Rev.* **254**, 207–224 (2013).
- 717 96. Malaspina, A., Moir, S., Ho, J., ... W. W.-P. of the & 2006, undefined. Appearance of
718 immature/transitional B cells in HIV-infected individuals with advanced disease:
719 correlation with increased IL-7. *Natl. Acad Sci.*
- 720 97. Malaspina, A. *et al.* Idiopathic CD4+ T lymphocytopenia is associated with increases
721 in immature/transitional B cells and serum levels of IL-7. *ashpublications.org*
- 722 98. Shah, H. B. *et al.* Insights from analysis of human antigen-specific memory B cell
723 repertoires. *Frontiers in Immunology* **10**, 3064 (2019).
- 724 99. Jones, C. E. *et al.* The impact of HIV exposure and maternal Mycobacterium
725 tuberculosis infection on infant immune responses to bacille Calmette-Guérin
726 vaccination. *AIDS* **29**, 155–165 (2015).
- 727 100. Miles, D. J. C. *et al.* Human immunodeficiency virus (HIV) infection during
728 pregnancy induces CD4 T-cell differentiation and modulates responses to Bacille
729 Calmette-Guérin (BCG) vaccine in HIV-uninfected infants. *Immunology* **129**, 446–454
730 (2010).
- 731 101. Moir, S. & Fauci, A. S. B cells in HIV infection and disease. *Nat Rev Immunol* **9**, 235–

- 732 245 (2009).
- 733 102. Abu-Raya, B., Smolen, K. K., Willems, F., Kollmann, T. R. & Marchant, A. Transfer
734 of Maternal Antimicrobial Immunity to HIV-Exposed Uninfected New-borns. *Front.*
735 *Immunol.* **7**, (2016).
- 736 103. Jallow, S., Cutland, C. L., Masbou, A. K., Adrian, P. & Madhi, S. A. Maternal HIV
737 infection associated with reduced transplacental transfer of measles antibodies and
738 increased susceptibility to disease. *J. Clin. Virol.* **94**, 50–56 (2017).
- 739 104. Ray, J. E. *et al.* Reduced Transplacental Transfer of Antimalarial Antibodies in
740 Kenyan HIV-Exposed Uninfected Infants. *Open forum Infect. Dis.* **6**, ofz237 (2019).
- 741 105. Dzanibe, S. *et al.* Reduced transplacental transfer of group b streptococcus surface
742 protein antibodies in HIV-infected mother-new-born dyads. *J. Infect. Dis.* **215**, 415–
743 419 (2017).
- 744 106. Cowgill, K. D. *et al.* Effectiveness of Haemophilus influenzae Type b Conjugate
745 Vaccine Introduction Into Routine Childhood Immunization in Kenya. *JAMA J. Am.*
746 *Med. Assoc.* **296**, 671–678 (2006).
- 747 107. Paul Dazaa Keystoxe Misoya, Agnes Katsulukuta, Bradford D. Gessner, Reggis
748 Katsande, Bekithemba R. Mhlanga, Judith E. Mueller, Christopher B. Nelson, Amos
749 Phiri, Elizabeth M. Molyneuxi, Malcolm E. Molyneuxh, R. B. *et al.* The impact of
750 routine infant immunization with Haemophilus influenzae type b conjugate vaccine in
751 Malawi, a country with high human immunodeficiency virus prevalence. *Vaccine* **24**,
752 6232–6239 (2006).
- 753 108. Madhi, S. a *et al.* Immunogenicity and effectiveness of Haemophilus influenzae type b
754 conjugate vaccine in HIV infected and uninfected African children. *Vaccine* **23**, 5517–
755 5525 (2005).

- 756 109. Jones, C. E. *et al.* Maternal HIV Infection and Antibody Responses Against Vaccine-
757 Preventable Diseases in Uninfected Infants. *JAMA* **305**, 576 (2011).
- 758 110. Simani, O. E. *et al.* Effect of HIV exposure and timing of antiretroviral therapy
759 initiation on immune memory responses to diphtheria, tetanus, whole cell pertussis and
760 hepatitis B vaccines. *Expert Rev. Vaccines* **18**, 95–104 (2019).
- 761 111. Gaensbauer, J. T. *et al.* Impaired haemophilus influenzae type b transplacental
762 antibody transmission and declining antibody avidity through the first year of life
763 represent potential vulnerabilities for HIV-exposed but -uninfected infants. *Clin.*
764 *Vaccine Immunol.* **21**, 1661–7 (2014).
- 765 112. Chadburn, C. *et al.* CD40-Independent Mechanism Involving Switch Recombination
766 through a HIV-1 Envelope Triggers Polyclonal Ig Class. *Am Assoc Immunol* (2020).
767 doi:10.4049/jimmunol.176.7.3931
- 768 113. Silverman, G., Immunology, C. G.-N. R. & 2006, undefined. Confounding B-cell
769 defences: lessons from a staphylococcal superantigen. *nature.com*
- 770 114. Rappocciolo, G. *et al.* DC-SIGN on B Lymphocytes Is Required For Transmission of
771 HIV-1 to T Lymphocytes. *PLoS Pathog.* **2**, e70 (2006).
- 772 115. Moir, S. *et al.* B cells of HIV-1-infected patients bind virions through CD21-
773 complement interactions and transmit infectious virus to activated T cells. *J. Exp. Med.*
774 **192**, 637–645 (2000).
- 775 116. Legrand, F. A. *et al.* Strong HIV-1-Specific T Cell Responses in HIV-1-Exposed
776 Uninfected Infants and Neonates Revealed after Regulatory T Cell Removal. *PLoS*
777 *One* **1**, e102 (2006).
- 778 117. Busby, E. *et al.* Instability of 8E5 calibration standard revealed by digital PCR risks
779 inaccurate quantification of HIV DNA in clinical samples by qPCR. *Sci. Rep.* **7**, 1209

- 780 (2017).
- 781 118. Yates, R. M., Hermetter, A. & Russell, D. G. The kinetics of phagosome maturation as
782 a function of phagosome/lysosome fusion and acquisition of hydrolytic activity.
783 *Traffic* **6**, 413–420 (2005).
- 784 119. Podinovskaia, M. *et al.* Dynamic quantitative assays of phagosomal function. *Curr.*
785 *Protoc. Immunol.* **102**, 14.34.1-14.34.14 (2013).
- 786 120. Kabilan, L. *et al.* Detection of intracellular expression and secretion of interferon-
787 gamma at the single-cell level after activation of human T cells with tetanus toxoid in
788 vitro. *Eur J Immunol* **20**, 1085–9 (1990).
- 789 121. Engvall, E. & Perlmann, P. Enzyme-linked immunosorbent assay (ELISA).
790 Quantitative assay of immunoglobulin G. *Immunochemistry* **8**, 871–4 (1971).
- 791 122. Wernette, C. M. *et al.* Enzyme-linked immunosorbent assay for quantitation of human
792 antibodies to pneumococcal polysaccharides. *Clin. Diagn. Lab. Immunol.* **10**, 514–9
793 (2003).
- 794 123. Rose, C. E. *et al.* Multilaboratory comparison of Streptococcus pneumoniae
795 opsonophagocytic killing assays and their level of agreement for the determination of
796 functional antibody activity in human reference sera. *Clin. Vaccine Immunol.* **18**, 135–
797 42 (2011).
- 798 124. WHO. *Weekly epidemiological record Relevé épidémiologique hebdomadaire.* (2006).
- 799 125. WHO. Tetanus vaccines: WHO position paper – February 2017. **92**, 53–76 (2017).
- 800 126. WHO. Diphtheria vaccine: WHO position paper – August 2017. **92**, 417–436 (2017).

801

802

804 **Tables**

805 **Table 1. Participant characteristics among HEU new-borns, infants and HUU controls**

806

	New-born Birth cohort			Longitudinal Infant cohort		
	HIV-	HIV+	<i>p-value</i>	HIV-	HIV+	<i>p-value</i>
^a Mothers age in years (IQR)	27.6 (23.6-32.95)	29.7(25.95-32.2)	0.86	21.9 (19.5-26.2)	28.8 (25.2-33.1)	0.37
^a Mothers ART no.(%)	N/A	34/34 (100)	-	N/A	37/43 (86)	-
^a Mothers time on ART months (range)	N/A	18.17 (1-143)	-	N/A	9.28 (0-72)	-
^a Mothers CD4+ cells μ L median (IQR)	N/A	294 (8-892)	N/A	N/A	409 (159-823)*	-
^a Mothers no. caesarean Section (%)	0/44 (0)	14/34 (39)	0.01	-	-	-
	HUU new-born	HEU new-born	<i>p-value</i>	HUU infant	HEU infant	<i>p-value</i>
^a Female Sex of child	22/44	15/34	0.65	29/61 (55)	22/43 (39)	0.24
HIV DNA PCR test result of child at birth	-	31/34 (100)		-	43/43	-
HIV DNA PCR test result of child at 6 weeks	-	34/34 (100)		-	36/43 (83.7)*	-

807

808 Abbreviations: IQR, interquartile range; No., number; %=percentage; μ L= microliter; dPCR=digital PCR, RDT = rapid diagnostic test

809 performed on whole blood. ^a Calculated using Mann-Whitney for continuous variables and Fishers exact test for categorical variables.

810 ^bResult indeterminant. *7/43 unconfirmed HIV status, **3 mothers had missing CD4 data, ***self-reported exclusive breastfeeding.

811

812

813

814

815

816 **Table 2. Robust opsonising and killing function of anti-pneumococcal capsular**
 817 **polysaccharide specific IgG antibodies in infant serum**

PCV13 Serotypes	HUU infants	HEU infants				
	GMOI (95% CI)	GMOI (95% CI)	HUU infants	HEU infants		
			GMC (95% CI)	GMC (95% CI)		
					<i>p-value</i>	
4	52.70 (12.02 – 231.1)	69.57 (8.32 – 581.9)	0.95	0.52 (0.19-1.42)	0.9	0.66
6B	39.97 (7.27 – 219.6)	65.58 (5.72 – 752.1)	0.76	0.39 (0.2-0.76)	0.55 (0.17-1.83)	0.75
14	169 (37.31 – 765.2)	223 (32.02 - 1553)	0.82	0.46 (0.2-1.08)	0.84 (0.21-3.3)	0.48
23F	48.82 (10.19 – 233.9)	78.70 (7.61 – 813.5)	0.80	0.38 (0.18-0.79)	0.51 (0.15-1.77)	0.99
6A	46.37 (5.9 – 364.3)	74.07 (5.68 – 966.9)	0.72	0.29 (0.16-0.52)	0.51 (0.15-1.8)	0.32
9V	65.79 (11.18 – 387.1)	82.85 (9.02 – 761.2)	0.93	0.4 (0.17-0.91)	0.74 (0.19-2.9)	0.42
18C	55.35 (11.88 - 258)	70.12 (8.6 – 570.9)	0.80	0.71 (0.24-2.07)	1.17 (0.18-7.48)	0.99
19F	74.04 (14.81-370.2)	92.55 (11.48-746)	0.93	0.65 (0.3-1.42)	1.08 (0.31-3.81)	0.49
1	11.22 (6.65-18.92)	16.39 (6.35-42.26)	0.49	2.19 (0.96-5.02)	2.5 (0.65-9.74)	0.82
5	17.79 (6.98-45.31)	26.98 (7.97-91.28)	0.44	0.53 (0.23-1.21)	0.62 (0.136-2.84)	0.83
7F	142.4 (25.17-805.4)	117.4 (10.02-1376)	0.87	0.63 (0.21-1.86)	1.20 (0.19-7.50)	0.66
19A	23.52 (6.64-83.31)	47.49 (5.76-391.3)	0.63	1.11 (0.33-3.72)	2.31 (0.4-13.37)	0.50
3	22.37 (8.4-59.54)	24.31 (6.58-89.82)	0.90	0.32 (0.15-0.7)	0.56 (0.2-1.63)	0.48

818

819 Abbreviations: GMOI (geometric mean opsonophagocytic index), GMC (geometric mean concentration) 95% CI (95% confidence interval),

820 PCV13 (pneumococcal conjugate vaccine 13) The geometric mean opsonic index (GMOI) and 95% confidence intervals (CI) of results are

821 reported for MOPA (HUU n = 11, HEU n = 9) ; the serotype-specific IgG geometric mean concentration (GMC) (HUU n = 11, HEU n = 8)

822 for all PCV13 serotypes (1, 3, 4, 5, 6 A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) are reported, less than 8 was reported as no response.

823

824 **Figure Legends**

825 **Figure 1. Monocyte phagosomal functional capacity in HEU new-borns and HUU**

826 **controls.** The proportion of CD14⁺ cells that performed **a)** phagosomal superoxide burst
827 activity, **b)** phagosomal bulk proteolytic activity, **c)** and that were associated with beads, **d)**
828 the phagosomal superoxide burst activity index and **e)** the phagosomal bulk proteolytic
829 activity index. The readout for the assay are reported as the median fluorescent intensity of
830 the reporter fluorochrome at 60mins:10mins and 240mins:10mins for oxidative burst and
831 bulk proteolysis, respectively. The activity index was calculated using a ratio of the reporter
832 fluorochrome over the the calibration fluorochrome. Only individuals with an uptake of
833 greater than $\geq 30\%$ were used in the phagosomal analysis. Data are presented as medians and
834 analysed using Mann Whitney U test (HUU, n=16; HEU, n=12).

835

836 **Figure 2: Characterisation of B cell immune profiles in HEU and HUU new-borns**

837 Cord blood was stained with the following fluorochrome-conjugated antibodies, anti-CD19
838 APC, anti-CD10 PE-Cy7, anti-CD21-FITC and anti-CD27 APC-CY7. Singlets were defined
839 using FSC-A vs. FSC-H parameters and lymphocytes were gated using SSC-A and FSC-A. B
840 cells were then gated using CD19 against SSC-A. **a)** The proportion of B cell subsets were
841 clasified using CD10, CD21 and CD27 as follows, **b)** CD10⁻CD21⁺CD27⁻ (naive), CD10⁻
842 CD21⁻CD27⁺ (resting memory), CD10⁻CD21⁺CD27⁺ (activated memory), CD10⁻CD21⁻
843 CD27⁻ (tissue-like memory) and **c)** CD10⁺CD27⁻ (immature transitional).
844 **d-e)** Expression of CD95e450, FcLR4 PE and PD-1 APC (exhausted and activatory inhibited
845 B-cells) were gated as a proportion of CD19⁺ cells.
846 Data are presented as medians [IQR] and analysed using Mann Whitney U test (HUU n=42,
847 HEU n=18).

848

849 **Figure 3. Characterisation of T cell subsets in HEU and HUU new-borns. a)** Whole cord
850 blood was stained with the following fluorochrome-conjugated antibodies, anti-CD3
851 APCCY7, anti-CD4 Pacific Blue, anti-CD8-FITC, anti-CCR7 APC and anti-CD45RA
852 PECY7. Singlets were defined using FSC-A vs. FSC-H parameters and lymphocytes were
853 gated using SSC-A and FSC-A. T cells were then gated using CD3 against SSC-A, then a
854 CD4 versus CD8 plot was used to separate the two main T cell subsets. **b)** CD4⁺ and CD8⁺ T
855 cell subsets were classified using CCR7 and CD45RA as follows CCR7-CD45RA⁻ (effector
856 memory), CCR7⁺CD45RA⁻ (central memory), CCR7⁺CD45RA⁺ (naïve) and CCR7⁻
857 CD45RA⁺(terminally-differentiated).

858 **c)** Whole cord blood was stained with the following fluorochrome-conjugated antibodies,
859 anti-CD3 APCCY7, anti-CD4 Pacific Blue, anti-CD8-PECY7 and CD57 FITC, PD1-PE.
860 Singlets were defined using FSC-A vs. FSC-H parameters and lymphocytes were gated using
861 SSC-A and FSC-A. T cells were then gated using CD3 against SSC-A, then a CD4 versus
862 CD8 plot was used to separate the two main T cell subsets. **d)** CD4⁺ and CD8⁺ T cell subsets
863 were classified using CD57 (senescent) and PD-1 (exhausted). (HUU, n =36; HEU, n =25). **e)**
864 Isolated CBMCs were incubated with PHA or PPD for 18 hours and IFN- γ producing cells
865 were detected on a 96-well microtitre ELISpot plate. The frequency of SFCs/million CBMCs
866 are plotted for all subjects. (HUU, n =34; HEU, n =22) Data analysed using Fisher's exact
867 test.

868

869 **Figure 4: Characterisation of B cell and T cell subsets in HEU and HUU infants**

870 Cord blood was stained with the following fluorochrome-conjugated antibodies, anti-CD19
871 APC, anti-CD10 PE-Cy7, anti-CD21-FITC and anti-CD27 PE. Singlets were defined using
872 FSC-A vs. FSC-H parameters and lymphocytes were gated using SSC-A and FSC-A. B cells
873 were then gated using CD19 against SSC-A. **a)** The proportion of B cell subsets were

874 classified using CD10, CD21 and CD27 as follows, **b)** CD10⁻CD21⁺CD27⁻ (naive), CD10⁻
875 CD21⁻CD27⁺ (resting memory), CD10⁻CD21⁺CD27⁺ (activated memory), CD10⁻CD21⁻
876 CD27⁻ (tissue-like memory) and **c)** CD10⁺CD27⁻ (immature transitional).
877 Whole blood was stained with the following fluorochrome-conjugated antibodies, anti-CD3
878 APCH7, anti-CD4 Pacific Blue, anti-CD8-FITC, anti-CCR7 APC and anti-CD45RA PE.
879 Singlets were defined using FSC-A vs. FSC-H parameters and lymphocytes were gated using
880 SSC-A and FSC-A. T cells were then gated using CD3 against SSC-A, then a CD4 versus
881 CD8 plot was used to separate the two main T cell subsets. **d-e)**CD4⁺ and CD8⁺ T cell
882 subsets were classified using CCR7 and CD45RA as follows CCR7⁻CD45RA⁻ (effector
883 memory), CCR7⁺CD45RA⁻ (central memory), CCR7⁺CD45RA⁺ (naïve) and CCR7⁻
884 CD45RA⁺(terminally-differentiated).
885 Data are presented as medians [IQR] and analysed using Mann Whitney U test (HUU n=42,
886 HEU n=31).

887

888 **Figure 5. Infant and maternal antibody responses.** Preceding and following Penta-
889 DTwPHibHepB vaccination we measured vaccine titers using an ELISA to **a)** anti-Hib IgG
890 **b)** anti-TT IgG **c)** anti-DT IgG in infant serum at 5-7 (HUU, n=50; HEU n=39), 14-15 (HUU,
891 n=22; HEU, n=27) and 18-23 (HUU, n=25; HEU, n=19) weeks. HIV- uninfected (n=61) and
892 HIV-infected (n=43) and maternal titres for **d)** anti-*Hib* IgG **e)** anti-TT IgG **f)** anti-DT IgG
893 are depicted. Blue circles are controls and red are HEU infants or HIV-infected mothers.
894 Green dotted horizontal line represents cut-off for protective titers. Data are presented as
895 medians and analysed using Mann Whitney U test. Minimum putative protective titres are
896 0.15ug/mL (passive) and 1.0ug/mL (acquired) for *Hib*¹²⁴, and 0.01IU/mL for TT¹²⁵and DT
897 ¹²⁶.

898

899 **Figure 6: Infant exposure to immune modulating viruses HCMV and HIV**

900 **a)** Detection of Gag-specific T-cells by T-cell ELISPOT assay in HUU and HEU infants, and
901 ART naïve/experienced HIV-infected adults . Isolated PBMCs were incubated with 15-mer
902 Gag peptide pool, PHA as a positive control or RPMI media as a negative control. IFN- γ
903 producing cells were detected on a 96-well microtitre ELISpot plate. **b)** The frequency of
904 SFCs/million PBMCs are plotted for all subjects. Data analysed using Fisher's exact test
905 (HUU, n =22; HEU, n=34; HIV+ART+, n=17; HIV+ART-, n=8). **c)** Plasma anti-CMV IgG
906 was measured in infants at 5-15weeks of age and assigned an arbitrary titer; blue circles are
907 HUU controls and red circles are HEU. Data are presented as medians [IQR] and analysed
908 using Mann Whitney U test (HUU n=57, HEU n=42). The proportion of **d)** HUU and HEU
909 infants and **e)** HIV-infected and uninfected mothers with RT-PCR detected CMV DNA in
910 their oropharangeal throat swab and breast milk respectively, (HIV- n=23, HIV+ n=35). The
911 proportion of **f)** HUU and HEU infants who were seropositive for anti-EBV IgG in their
912 plasma (HUU n=57, HEU n=42) and **g)** mothers who had detectable EBNA4 protein by RT-
913 PCR, (HIV- n=23, HIV+ n=35). Data analysed using Fisher's exact test and effective size
914 reported as a relative risk.

915

916

917 **Supplementary Figures**

918 **Supplementary Figure 1: Gating strategy to detect monocyte phagosomal functional**

919 **capacity at birth.** Singlets were defined using FSC-A vs. FSC-H parameters and
920 lymphocytes were gated using SSC-A and CD14 PE-CY7. Then FSC-A vs. AF405 to gate
921 cells with beads. The readout for the assay are reported as the median fluorescent intensity of
922 the reporter fluorochrome at 60mins:10mins and 240mins:10mins for oxidative burst and
923 bulk proteolysis, respectively. The activity index was calculated using a ratio of the reporter

924 fluorochrome over the the calibration fluorochrome. Only individuals with an uptake of
925 greater than $\geq 30\%$ were used in the phagosomal analysis.

926

927 **Supplementary Figure 2: Gating strategy to characterise B cells.** a) Blood was stained
928 with the following fluorochrome-conjugated antibodies, anti-CD19 APC, anti-CD10 PE-Cy7,
929 anti-CD21-FITC and anti-CD27 PE. Singlets were defined using FSC-A vs. FSC-H
930 parameters and lymphocytes were gated using SSC-A and FSC-A. B cells were then gated
931 using CD19 against SSC-A. The following populations were determined: CD10⁻
932 CD21⁺CD27⁻ (naive), CD10⁻CD21⁻CD27⁺ (resting memory), CD10⁻CD21⁺CD27⁺ (activated
933 memory), CD10⁻CD21⁻CD27⁻ (tissue-like memory) and c) CD10⁺CD27⁻ (immature
934 transitional). b) Blood was stained with CD19 PERCP, anti-CD10 PE-Cy7, anti-CD21-FITC
935 and anti-CD27 APCCY7, FcRL4 PE, CD95e450 and CD27 APCCY7 to determine B cells
936 expressing inhibitory markers.

937

938

939 **Supplementary Figure 3: IFN- γ producing cells to HIV protein GAG at birth**

940 A 15-mer GAG peptide pool was used to stimulate isolated CBMCs from cord blood in an
941 18hour T cell EliSpot assay. IFN- γ producing cells were detected on a 96-well microtitre
942 ELISpot plate. a) The frequency of GAG SFCs/million CBMCs are plotted for all subjects.
943 Data analysed using Fisher's exact test (HUU, n =35; HEU, n=23).

944

945 **Supplementary Figure 4: Gating strategy to characterise T cell subsets.** a) Whole blood
946 was stained with the following fluorochrome-conjugated antibodies, anti-CD3 APCH7, anti-
947 CD4 Pacific Blue, anti-CD8-FITC, anti-CCR7 APC and anti-CD45RA PE. b) Cord blood
948 was stained with the following fluorochrome-conjugated antibodies, anti-CD3 APCY7, anti-

949 CD4 Pacific Blue, anti-CD8-PECY7, anti-CCR7 APC and anti-CD45RA PECY5, PD-1 PE
950 and CD57 FITC.
951 Singlets were defined using FSC-A vs. FSC-H parameters and lymphocytes were gated using
952 SSC-A and FSC-A. T cells were then gated using CD3 against SSC-A, then a CD4 versus
953 CD8 plot was used to separate the two main T cell subsets. FMO were used to determine
954 gating. CD4⁺ and CD8⁺ T cell subsets were classified using CCR7 and CD45RA as follows
955 CCR7-CD45RA⁻ (effector memory), CCR7⁺CD45RA⁻ (central memory), CCR7⁺CD45RA⁺
956 (naïve) and CCR7⁻CD45RA⁺(terminally-differentiated).

957

958 **Supplementary Figure 5: IFN- γ producing cells to vaccine antigens in HEU and HUU**
959 **infants**

960 Detection of IFN- γ producing cells using a T-cell ELISPOT assay in HUU and HEU infants..
961 Isolated PBMCs were incubated with either PPD, TT, Hb or PHA as a positive control or
962 RPMI media as a negative control for 18 hours. IFN- γ producing cells were detected on a 96-
963 well microtitre ELISpot plate. **a)** The frequency of SFCs/million PBMCs are plotted for all
964 subjects. Data analysed using Fisher's exact test (HUU, n =22; HEU, n=34).

965

966 **Supplementary Table**

967 **Supplementary Table 1. Fluorochromes**

968

969 **Supplementary Table 2. Fluorescent antibody panels**

970

Figure 1




Figure 2








Figure 3



a.




b.



c.



d.



e.




Figure 4






Figure 5






Figure 6




Supplementary Figure 1 – CORD BLOOD




Supplementary Figure 2

a.




b.



Supplementary Figure 3 – CORD BLOOD


a.



Supplementary Figure 4

infant blood


a.




Gating control - FMO

b.

Cord blood



Supplementary Figure 5 - INFANT



Supplementary Table 1 – Fluorochromes

a.

Marker	Fluorochrome	Clone	Manufacturer	Filter ex/em	Isotype
CD3	APC-H7	SK7 (Leu-4)	BD	640/785	Mouse BALB/c IgG ₁ , k
CD4	Pacific Blue	RPA-T4	BD	401/452	Mouse IgG ₁ , k
CD8	FITC	RPA-T8	BD	494/520	Mouse IgG ₁ , k
CD19	APC	H1B19	BD	633/650	Mouse IgG ₁ , k
CD27	PE	M-T271	BD	496/578	Mouse BALB/c IgG1, k
CD27	APC-Cy7	M-T271	Biolegend	633/	Mouse IgG ₁ , k
CD14	PE-Cy7	M5E2	BD	496/785	Mouse IgG2a, k
CD10	PE-Cy7	HI10a	BD	496/785	Mouse BALB/c IgG1, k
CD21	FITC	B-ly4	BD	494/520	Mouse IgG ₁ , k
CD45RA	PE	HI100	BD	496/578	Mouse IgG _{2b} , k
CCR7	APC	2-L1-A	BD	650/660	Mouse BALB/c IgG1, k
CD95	efluor450	DX2	eBioscience	405/450	Mouse IgG ₁ , k
FcRL4	PE	413D12	Biolegend	496/578	Mouse IgG2b,k
PD-1	APC	MIH4	BD	650/660	Mouse IgG1,k
CD57	FITC	Leu-7	BD	494/520	Mouse IgM,k

Supplementary Table 2 – Fluorescent antibody panels

a.

Panel 1	Panel 2	Panel 3	Panel 4	Panel 5
anti-CD14 Phycoerythrin Cyanine-7 (PECy7)	anti-CD19 Allophycocyanin (APC)	anti-CD19 Peridinin- Chlorophyll- Protein (PERCP)	anti-CD3 Allophycocyanin- H7 (APC-H7)	anti-CD3 Allophycocyanin -H7 (APC-H7)
anti-AF405 Beads	anti-CD10 PE- Cy7	anti-CD10 PE-Cy7	anti-CD4 Pacific Blue (PB)	anti-CD4 Pacific Blue (PB)
	anti-CD21 FITC	anti-CD21 FITC	anti-CD8 Fluorescein (FITC)	anti-CD8 (PECY7)
	anti-CD27 (PE)	anti-CD27 APC- Cy7	anti-CD45RA Phycoerythrin (PE)	anti-CD45RA PECY5
		anti-CD95 e450	anti-CCR7 Allophycocyanin (APC)	anti-CD57 FITC
		anti-FcLR4 PE		anti-PD-1 PE
		anti-PD -1 APC		